Tackling Antimicrobial Resistance in the Shadow of COVID-19.
mBio
; 12(4): e0047321, 2021 08 31.
Article
in English
| MEDLINE | ID: covidwho-1318003
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic is a challenge for ongoing efforts to combat antimicrobial-resistant (AMR) bacterial infections. As we learn more about COVID-19 disease and drug stewardship evolves, there is likely to be a lasting impact of increased use of antimicrobial agents and antibiotics, as well as a lack of consistent access to health care across many populations. Sexually transmitted infections have been underreported during the pandemic and are often caused by some of the most drug-resistant pathogens. In their recent article in mBio, Parzych et al. (E. M. Parzych, S. Gulati, B. Zheng, M. A. Bah, et al., mBio 12e00242-21, 2021, https//doi.org/10.1128/mBio.00242-21) focus on protection against Neisseria gonorrhoeae infection via in vivo delivery of an antigonococcal DNA-encoded antibody that has been modified for increased complement activation. Nucleic acid approaches are highly adaptable and could be tremendously beneficial for personalized strategies to combat AMR pathogens.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug Resistance, Multiple, Bacterial
/
Antimicrobial Stewardship
/
COVID-19
/
Anti-Bacterial Agents
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
MBio
Year:
2021
Document Type:
Article
Affiliation country:
MBio.00473-21
Similar
MEDLINE
...
LILACS
LIS